Ipsen (XPAR:IPN) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:IPN Ipsen SA XPAR:IPN
96 GF Score
Price €160.60
GF Value €134.33
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

XPAR:IPN
96GF Score
Ipsen SA XPAR:IPN
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (XPAR:IPN) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €160.60 is trading 19.6% above its estimated GF Value™ of €134.33. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for XPAR:IPN:

  • Dividends Received:
  • GF Value™: €134.33 vs. price of €160.60 (19.6% above fair value)
  • GF Score™: 96/100 with 7 warning signs

No single metric tells the full story. See the XPAR:IPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
96GF Score

Get the complete analysis for XPAR:IPN

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€160.60
Price
€134.33
GF Value